NASDAQ:CGEN - Compugen Stock Price, Price Target & More

$4.13 -0.07 (-1.67 %)

(As of 04/20/2018 10:42 AM ET)

Previous Close$4.20

Today's Range$4.05 - $4.25

52-Week Range$2.25 - $5.40

Volume39,546 shs

Average Volume291,265 shs

Market Capitalization$223.13 million

P/E Ratio-5.83

Dividend YieldN/A

Beta0.26

About Compugen (NASDAQ:CGEN)

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:CGEN

CUSIPN/A

Webwww.cgen.com

Phone972-3765-8585

Debt

Debt-to-Equity RatioN/A

Current Ratio5.04%

Quick Ratio5.04%

Price-To-Earnings

Trailing P/E Ratio-5.83

Forward P/E Ratio-5.51

P/E GrowthN/A

Sales & Book Value

Annual Sales$710,000.00

Price / Sales298.35

Cash FlowN/A

Price / CashN/A

Book Value$0.57 per share

Price / Book7.25

Profitability

EPS (Most Recent Fiscal Year)($0.72)

Net Income$-37,060,000.00

Net MarginsN/A

Return on Equity-87.08%

Return on Assets-72.10%

Miscellaneous

Employees98

Outstanding Shares51,290,000

How to Become a New Pot Stock Millionaire

Compugen (NASDAQ:CGEN) Frequently Asked Questions

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen (NASDAQ:CGEN) posted its quarterly earnings data on Wednesday, February, 21st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter. View Compugen's Earnings History.

When is Compugen's next earnings date?

Compugen is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Compugen.

What price target have analysts set for CGEN?

3 brokerages have issued 12 month price targets for Compugen's shares. Their predictions range from $9.00 to $14.00. On average, they expect Compugen's stock price to reach $11.50 in the next year. View Analyst Ratings for Compugen.

Who are some of Compugen's key competitors?

Some companies that are related to Compugen include Agenus (AGEN), Nightstar Therapeutics (NITE), Idera Pharmaceuticals (IDRA), Solid Biosciences (SLDB), Cellular Biomedicine (CBMG), Adverum Biotechnologies (ADVM), NantKwest (NK), Allena Pharmaceuticals (ALNA), Fennec Pharmaceuticals (FENC), Osiris Therapeutics (OSIR), NanoString Technologies (NSTG), Arsanis (ASNS), ADMA Biologics (ADMA), Pluristem Therapeutics (PSTI), Organovo (ONVO), Eiger Biopharmaceuticals (EIGR), Lorus Therapeutics (APTO) and Curis (CRIS).

Who are Compugen's key executives?

Compugen's management team includes the folowing people:

Dr. Anat Cohen-Dayag, Chief Exec. Officer, Pres and Director (Age 51)
Mr. Ari Krashin, Chief Financial and Operating Officer (Age 45)
Dr. Zurit Levine Ph.D., VP of Research & Discovery (Age 50)
Dr. John J. Hunter, VP of Antibody R&D (Age 55)
Mr. Martin S. Gerstel, Sr. Advisor (Age 77)

Has Compugen been receiving favorable news coverage?

News stories about CGEN stock have trended somewhat positive on Friday, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Compugen earned a media sentiment score of 0.04 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 45.65 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $4.07.

How big of a company is Compugen?

Compugen has a market capitalization of $223.13 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 98 workers across the globe.

How can I contact Compugen?

Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]

MarketBeat Community Rating for Compugen (CGEN)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		180 (Vote Outperform)
Underperform Votes:		147 (Vote Underperform)
Total Votes:		327

MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Compugen (NASDAQ:CGEN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Compugen in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 178.45%. The high price target for CGEN is $14.00 and the low price target for CGEN is $9.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$11.50	$14.00	$14.00	$14.00
Price Target Upside:	178.45% upside	225.58% upside	225.58% upside	225.58% upside

Compugen (NASDAQ:CGEN) Consensus Price Target History

Price Target History for Compugen (NASDAQ:CGEN)

Compugen (NASDAQ:CGEN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/29/2018	CIBC	Initiated Coverage	Outperform -> Outperform		Low
3/29/2018	Oppenheimer	Initiated Coverage	Outperform	$9.00	High
5/19/2017	FBR & Co	Set Price Target	Buy	$14.00	High

(Data available from 4/20/2016 forward)

Compugen (NASDAQ:CGEN) Earnings History and Estimates Chart

Earnings by Quarter for Compugen (NASDAQ:CGEN)

Compugen (NASDAQ:CGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.76)
2019 EPS Consensus Estimate: ($0.58)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.21)	($0.21)	($0.21)
Q2 2018	2	($0.21)	($0.18)	($0.20)
Q3 2018	2	($0.21)	($0.18)	($0.20)
Q4 2018	2	($0.22)	($0.10)	($0.16)
Q1 2019	1	($0.15)	($0.15)	($0.15)
Q2 2019	1	($0.14)	($0.14)	($0.14)
Q3 2019	1	($0.14)	($0.14)	($0.14)
Q4 2019	1	($0.15)	($0.15)	($0.15)

Compugen (NASDAQ CGEN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018
2/21/2018	n/a		($0.18)			View	N/A
11/7/2017	Q3 2017	($0.19)	($0.19)			View	N/A
8/2/2017	6/30/2017	($0.17)	($0.18)	$0.21 million		View	Listen
5/9/2017	3/31/2017	($0.18)	($0.17)	$0.06 million		View	Listen
2/15/2017	Q416	($0.18)	($0.17)	$0.13 million	$0.05 million	View	Listen
11/7/2016	Q316	($0.14)	($0.15)	$0.41 million	$0.07 million	View	N/A
8/2/2016	Q116	($0.17)	($0.13)	$0.11 million	$0.50 million	View	N/A
5/10/2016	Q1	($0.16)	($0.17)	$0.12 million	$0.09 million	View	Listen
2/9/2016	Q415	($0.11)	($0.01)	$3.33 million	$8.30 million	View	N/A
11/3/2015	Q315	($0.15)	($0.13)	$0.92 million	$0.23 million	View	N/A
8/4/2015	Q215	($0.14)	($0.14)	$1.58 million	$0.22 million	View	N/A
5/5/2015	Q115	($0.13)	($0.12)	$1.88 million	$0.51 million	View	N/A
2/10/2015	Q414	($0.08)	($0.03)	$3.70 million	$6.60 million	View	N/A
10/29/2014	Q314	($0.11)	($0.11)	$1.90 million	$1.70 million	View	N/A
8/6/2014	Q214	($0.10)	($0.07)	$1.85 million	$2.00 million	View	N/A
5/19/2014	Q114	($0.11)	($0.04)	$0.1620 million	$2.10 million	View	N/A
2/11/2014	Q413		($0.09)	$0.1320 million	$1.80 million	View	N/A
10/29/2013	Q313		($0.12)	$0.1080 million	$1.60 million	View	N/A
8/2/2013	Q2 2013		($0.09)		$0.02 million	View	N/A
4/25/2013	Q1 2013		($0.09)		$0.16 million	View	N/A
2/20/2013	Q4 2012		($0.15)			View	N/A
11/5/2012	Q312		($0.10)			View	N/A
8/7/2012	Q2 2012		($0.02)			View	N/A
5/1/2012	Q1 2012		($0.12)			View	N/A
2/7/2012	Q4 2011		($0.13)			View	N/A
11/8/2011	Q3 2011		($0.10)			View	N/A
8/2/2011	Q2 2011		($0.06)			View	N/A
5/11/2011	Q1 2011		($0.06)			View	N/A
2/15/2011	Q4 2010		($0.06)			View	N/A
10/26/2010	Q3 2010		($0.05)			View	N/A
7/27/2010	Q2 2010	($0.06)	($0.03)			View	N/A
4/27/2010	Q1 2010	($0.05)	($0.08)			View	N/A
2/9/2010	Q4 2009	($0.08)	($0.07)			View	N/A
10/27/2009	Q3 2009	($0.07)	($0.06)			View	N/A
7/28/2009	Q2 2009		$0.08			View	N/A
5/12/2009	Q1 2009		($0.08)			View	N/A
2/11/2009	Q4 2008		($0.13)			View	N/A
11/13/2008	Q3 2008		($0.12)			View	N/A
7/29/2008	Q2 2008		($0.10)			View	N/A
5/14/2008	Q1 2008		($0.09)			View	N/A
2/19/2008	Q4 2007		($0.11)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Compugen (NASDAQ:CGEN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Compugen (NASDAQ CGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.50%
Institutional Ownership Percentage: 21.17%

Insider Trading History for Compugen (NASDAQ:CGEN)

Institutional Ownership by Quarter for Compugen (NASDAQ:CGEN)

Compugen (NASDAQ CGEN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

Compugen (NASDAQ CGEN) News Headlines

Source:

Date	Headline
	Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen’s BAY 1905254 Efficacy in Cancer Immunotherapy finance.yahoo.com - April 19 at 8:32 AM
	Bayer's ILDR2 inhibitor shows encouraging action in preclinical studies, discoverer Compugen up 4% seekingalpha.com - April 17 at 10:12 AM
	BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018 www.reuters.com - April 17 at 8:53 AM
	Compugen (CGEN) Reports Preclinical Data by Bayer AG Highlighting Efficacy of BAY 1905254 (formerly the CGEN ... www.streetinsider.com - April 17 at 8:53 AM
	Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy finance.yahoo.com - April 17 at 8:53 AM
	Compugen's (CGEN) CEO Anat Cohen-Dayag on MedImmune License Agreement Call (Transcript) seekingalpha.com - April 5 at 5:06 PM
	Zacks: Analysts Anticipate Compugen (CGEN) Will Announce Earnings of -$0.20 Per Share www.americanbankingnews.com - April 5 at 9:42 AM
	Oppenheimer Research Analysts Decrease Earnings Estimates for Compugen (CGEN) www.americanbankingnews.com - April 5 at 8:52 AM
	[$$] AstraZeneca receives regulatory boost for oncology drugs finance.yahoo.com - April 3 at 5:18 PM
	Compugen Takes Lumps After AstraZeneca Pact www.baystreet.ca - April 2 at 5:13 PM
	Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi ... www.prnewswire.com - April 2 at 5:13 PM
	Compugen (CGEN) Announces Pact With MedImmune for Development of Bi-Specific and Multi-Specific Antibody ... www.streetinsider.com - April 2 at 9:00 AM
	Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products finance.yahoo.com - April 2 at 9:00 AM
	Compugen (CGEN) Lowered to "Strong Sell" at ValuEngine www.americanbankingnews.com - March 31 at 3:20 PM
	Oppenheimer Comments on Compugen Ltd.'s Q1 2019 Earnings (CGEN) www.americanbankingnews.com - March 30 at 7:24 AM
	Compugen (CGEN) Earns Outperform Rating from Analysts at CIBC www.americanbankingnews.com - March 29 at 10:49 PM
	Benzinga's Top Upgrades, Downgrades For March 29, 2018 www.benzinga.com - March 29 at 5:16 PM
	UPDATE: Oppenheimer Starts Compugen (CGEN) at Outperform www.streetinsider.com - March 29 at 8:45 AM
	Compugen (CGEN) Now Covered by Oppenheimer www.americanbankingnews.com - March 29 at 8:36 AM
	Compugen: Near-Term Catalysts Will Force Significant Revaluation seekingalpha.com - March 28 at 5:07 PM
	At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy? finance.yahoo.com - March 28 at 5:07 PM
	Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer finance.yahoo.com - March 26 at 8:38 AM
	Compugen Ltd (NASDAQ:CGEN): Should The Future Outlook Worry You? finance.yahoo.com - March 20 at 5:05 PM
	Compugen (CGEN) Downgraded by ValuEngine www.americanbankingnews.com - March 20 at 12:54 AM
	-$0.21 Earnings Per Share Expected for Compugen Ltd. (CGEN) This Quarter www.americanbankingnews.com - March 19 at 7:56 AM
	Analyzing Compugen (CGEN) and Ionis Pharmaceuticals (IONS) www.americanbankingnews.com - March 11 at 6:02 AM
	Compugen to Present at the Cowen and Company 38th Annual Health Care Conference finance.yahoo.com - March 8 at 8:42 AM
	Compugen (CGEN) Raised to "Hold" at ValuEngine www.americanbankingnews.com - March 4 at 10:00 PM
	ARK Investment Management LLC Purchases 1,103,384 Shares of Compugen Ltd. (CGEN) www.americanbankingnews.com - February 27 at 4:24 AM
	Compugen (CGEN) Downgraded by Zacks Investment Research to "Sell" www.americanbankingnews.com - February 26 at 7:40 PM
	FY2018 EPS Estimates for Compugen Ltd. (CGEN) Cut by Jefferies Group www.americanbankingnews.com - February 26 at 7:58 AM
	Financial Analysis: Compugen (CGEN) vs. Senomyx (SNMX) www.americanbankingnews.com - February 24 at 9:26 AM
	Compugen Ltd. Expected to Post Q1 2018 Earnings of ($0.21) Per Share (CGEN) www.americanbankingnews.com - February 23 at 10:02 AM
	Form 6-K COMPUGEN LTD For: Feb 21 - StreetInsider.com - StreetInsider.com www.streetinsider.com - February 23 at 8:39 AM
	Compugen Ltd.: An Undervalued Disruptive Innovation Company - Seeking Alpha seekingalpha.com - February 22 at 8:35 AM
	Compugen (CGEN) Releases Earnings Results www.americanbankingnews.com - February 21 at 12:10 PM
	Form 6-K COMPUGEN LTD For: Feb 21 www.streetinsider.com - February 21 at 8:37 AM
	Compugen Reports Fourth Quarter and Full Year 2017 Results www.prnewswire.com - February 21 at 7:27 AM
	Compugen (CGEN) to Release Quarterly Earnings on Wednesday www.americanbankingnews.com - February 14 at 4:50 AM
	Wired News – Compugen Reports Publication of Discovery and Validation of ILDR2 as A Novel Immune Checkpoint and Its Use for Auto-Immune Diseases finance.yahoo.com - February 8 at 8:21 AM
	Compugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ET finance.yahoo.com - February 8 at 8:21 AM
	Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology finance.yahoo.com - February 6 at 9:41 AM
	Compugen (CGEN) & Yield10 Bioscience (YTEN) Critical Comparison www.americanbankingnews.com - February 3 at 2:44 PM
	Compugen (CGEN) Downgraded by Zacks Investment Research www.americanbankingnews.com - January 22 at 7:52 PM
	Zacks Investment Research Upgrades Compugen (CGEN) to "Buy" www.americanbankingnews.com - January 19 at 8:44 PM
	Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors finance.yahoo.com - January 18 at 11:00 AM
	Compugen (CGEN) Lifted to "Hold" at Zacks Investment Research www.americanbankingnews.com - January 9 at 7:12 PM
	Contrasting NewLink Genetics (NLNK) & Compugen (CGEN) www.americanbankingnews.com - January 7 at 1:10 AM
	Compugen Announces Presentations at Three Upcoming Cancer ... - PR Newswire (press release) www.prnewswire.com - January 2 at 9:57 AM
	Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences finance.yahoo.com - January 2 at 9:57 AM

Compugen (NASDAQ:CGEN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Compugen (NASDAQ:CGEN) Income Statement, Balance Sheet and Cash Flow Statement

Compugen (NASDAQ CGEN) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff